Cover

Medical Genetics in the Clinical Practice of ORL

Editor(s): Alford R.L. (Houston, Tex.) 
Sutton V.R. (Houston, Tex.) 
Table of Contents
Vol. 70, 2011
Section title: Paper
Alford RL, Sutton VR (eds): Medical Genetics in the Clinical Practice of ORL. Adv Otorhinolaryngol. Basel, Karger, 2011, vol 70, pp 66–74
(DOI:10.1159/000322474)
Paper

Genetic Disorders with both Hearing Loss and Cardiovascular Abnormalities

Belmont J.W. · Craigen W.J. · Martinez H. · Jefferies J.L.
Departments of Molecular and Human Genetics, and Pediatrics, Baylor College of Medicine, Houston, Tex., USA

Abstract

There has been a growing appreciation for conditions that affect hearing and which are accompanied by significant cardiovascular disorders. In this chapter we consider several broad classes of conditions including deafness due to abnormal structural development of the inner ear, those with physiological abnormalities in the inner ear sensory apparatus, and conditions with progressive loss of function of sensory cells or middle ear functions. Because of shared developmental controls, inner ear malformations are often associated with congenital heart defects and can be part of complex syndromes that affect other organs and neurodevelopmental outcome. Physiological disorders of the hair cells can lead to hearing loss and can be associated with cardiac arrhythmias, especially long QT syndrome. In addition, cellular energy defects such as mitochondrial disorders can affect maintenance of hair cells and are often associated with cardiomyopathy. Lysosomal storage diseases and other disorders affecting connective tissue can lead to chronic middle ear disease, with conductive hearing loss and also cause cardiac valve disease and/or cardiomyopathy. The genetic basis for these conditions is heterogeneous and includes chromosomal/genomic disorders, de novo dominant mutations, and familial dominant, autosomal-recessive, and mitochondrial (matrilineal) inheritance. Taken together, there are more than 100 individual genes implicated in genetic hearing impairment that are also associated with congenital and/or progressive cardiac abnormalities. These genes encode transcription factors, chromatin remodeling factors, components of signal transduction pathways, ion channels, mitochondrial proteins and assembly factors,

 goto top of outline Author Contacts

John W. Belmont, MD, PhD, Departments of Molecular and Human Genetics, and Pediatrics, Children’s Nutrition Research Center, 1100 Bates, Room 8070, Houston, TX 77030 (USA), Tel. +1 713 798 4634, Fax +1 713 798 7187, E-Mail jbelmont@bcm.edu


 goto top of outline Article Information

Published online: February 24, 2011
Number of Print Pages : 9


 goto top of outline Publication Details

Book Serie: Advances in Oto-Rhino-Laryngology, Vol. 70, Year 2011

Editor(s): Arnold, W. (Munich); Randolph, G. (Boston, Mass.)
ISSN: 0065-3071 (Print), eISSN: 1662-2847 (Online)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0065-3071

Book Title: Medical Genetics in the Clinical Practice of ORL

Editor(s): Alford RL, Sutton VR (eds)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0065-3071&volume=70


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.